Search the Newsreel

HC Wainwright Forecasts Q32 Bio's Q3 Earnings (NASDAQ:QTTB)

HC Wainwright has updated its Q3 2026 EPS forecast for Q32 Bio (NASDAQ:QTTB), improving the estimate to a loss of $0.32 per share from a previous $0.50 loss, while maintaining a "Buy" rating and a $36 price target. The company recently reported a Q2 …

Q32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Moderate Buy" from Brokerages

Q32 Bio Inc. (NASDAQ:QTTB) has received a "Moderate Buy" consensus rating from six brokerages, with an average 12-month price target of $30.00, significantly higher than its current price of $16.49. Company insiders, including Director Diyong Xu and Orbimed Advisors Llc, have made substantial purchases …

Q32 Bio Inc. 2Q 2026: Net loss $(8.95)M, EPS $(0.44) — 10-Q Summary

Q32 Bio Inc. reported a net loss of $(8.95)M for the second quarter of 2026, an improvement from the prior year, though the company remains pre-revenue. Diluted loss per share was $(0.44). The company highlighted positive Phase 2a clinical results for bempikibart, a shift …

Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary

Q32 Bio Inc. has reported its financial results for the quarter that ended on June 30. The brief article, sourced from Reuters, serves as an earnings summary, indicating the availability of the full report for subscribers on TradingView.

Q32 Bio (NASDAQ:QTTB) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Q32 Bio (Nasdaq: QTTB) adds $187.6M follow-on cash for AA drug

Q32 Bio Inc. (QTTB) has significantly strengthened its liquidity by adding $187.6 million in net proceeds from a follow-on public offering completed on July 16, 2026. This comes after previous capital raises in 2026 through a registered direct offering ($10.4 million), an at-the-market program …

QTTB Stock Price and Chart — NASDAQ:QTTB

This page provides a detailed overview of Q32 Bio Inc. (NASDAQ: QTTB) stock, including its current price, performance over various periods, key financial statistics, and analyst ratings. It also features information on the company's operations, upcoming earnings dates, and ETFs that hold the stock.

Q32 Bio Inc. 2026 Q2 SEC Filing: Key Risks, Financials, and Forward-Looking Statements for Investors

Q32 Bio Inc. has released its Q2 2026 financial results, showing an improved liquidity position with total assets increasing significantly to $115.9 million. However, the company continues to operate at a loss with an accumulated deficit of $221.5 million and has issued a substantial …

Q32 Bio tops estimates as alopecia drug advances toward late-stage trials (QTTB:NASDAQ)

Q32 Bio (QTTB) reported a smaller second-quarter loss than anticipated, with its net loss narrowing to $8.9 million. This positive financial update, coupled with the advancement of its lead alopecia areata treatment candidate towards late-stage trials, led to a 1.5% rise in its shares …

Q32 Bio (Nasdaq: QTTB) reports AA trial gains and $200M raise

Q32 Bio reported its second-quarter 2026 financial results, including a net loss of $8.9 million, and significant progress in its alopecia areata program. The company's bempikibart drug achieved a 35.3% mean reduction in SALT score in a Phase 2a trial for severe and very …

Q32 Bio (QTTB) Earnings Date and Reports 2026

Q32 Bio Inc. Revenue Breakdown – NASDAQ:QTTB

Q32 Bio Inc. (NASDAQ: QTTB) reported its revenue breakdown, with its Novel Biologics segment being the top performer. The company generated $53.74 million USD last year, a significant increase from $1.16 million USD the previous year, with all of its revenue coming from the …

Q32 Bio Inc. (QTTB) investors disclose 5.49% stake in Schedule 13G/A

Opaleye, L.P., Opaleye Management Inc., and James Silverman have collectively disclosed a 5.49% beneficial ownership stake in Q32 Bio Inc. (QTTB) through a Schedule 13G/A filing. The reporting persons beneficially own 931,000 shares of QTTB's Common Stock, based on 16,956,415 shares outstanding as of …

Q32 Bio Inc expected to post a loss of 54 cents a share - Earnings Preview

Q32 Bio Inc is expected to report a loss of 54 cents per share. This information comes from an earnings preview provided by Refinitiv. The full article is available through a TradingView subscription.

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

Wall Street analysts project a significant upside for Q32 Bio (QTTB), with a mean price target of $44.5 suggesting a potential 186% surge from its current price of $15.56. While analysts' price targets can be overly optimistic, the strong agreement among them regarding higher …

Q32 Bio Inc. SEC Filing (Jul 29, 2026)

Q32 Bio Inc. (NASDAQ: QTTB) had a Notice of Effectiveness for its S-3 filing, effective July 28, 2026, at 4:01 P.M. The SEC accepted the filing on July 29, 2026, at 06:46 AM, with it becoming available on EDGAR at 12:15 AM on the …

QTTB|Q32 Bio Inc|Price:15.670|Chg%:+0.460

This article provides a comprehensive stock analysis of Q32 Bio Inc (QTTB) from

Q32 Bio (QTTB) Projected to Post Earnings on Wednesday

H.C. Wainwright raises Q32 Bio stock price target to $36 on alopecia drug outlook

H.C. Wainwright has increased its price target for Q32 Bio Inc. (NASDAQ:QTTB) to $36 from $23, maintaining a Buy rating due to the promising outlook for its alopecia drug, bempikibart. The firm raised the probability of success for bempikibart to 60% and significantly increased …

Q32 Bio Inc (QTTB) Balance Sheet

This article provides the balance sheet for Q32 Bio Inc (QTTB), offering quarterly and annual financial statements to assess the company's financial health, liquidity, leverage, and return on equity. It details various financial metrics including cash and investments, total assets, current and non-current liabilities, …

Q32 Bio Inc (QTTB) Cash Flow

This article provides a detailed cash flow statement for Q32 Bio Inc (QTTB), breaking down its operating, investing, and financing cash flows on a quarterly and annual basis. It includes historical data spanning several years, percentage changes, and specific monetary figures. The content also …

Q32 Bio Inc Revenue Breakdown – DUS:DB0

The article details the revenue breakdown for Q32 Bio Inc (DB0) for the last fiscal year, showing a total revenue of 45.75 million EUR. The Novel Biologics segment contributed the entirety of this revenue, a significant increase from the previous year. All reported revenue …

Q32 Bio Inc (QTTB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Q32 Bio Inc (QTTB) has an earnings forecast score of 8.00, placing it 168th out of 386 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $10.00, with a high of $20.00 and a low of $4.00, and …

Form 13D/A Q32 Bio Inc. For: 21 July By Investing.com

This article announces the filing of Form 13D/A for Q32 Bio Inc. on July 21st. The filing pertains to stock market activities and indicates a -2.14% change for the company's stock symbol QTTB. The content also includes various financial market data and popular news …

Q32 Bio Inc. (QTTB) corrects director stock option grant to 10,826 options

Q32 Bio Inc. (QTTB) has filed an amended Form 4 to correct a previously reported stock option grant to director Arthur Tzianabos. The corrected filing states that Tzianabos was granted 10,826 stock options with an exercise price of $12.64 per share and an expiration …

Q32 Bio Inc. (QTTB) director awarded 10,826 options at $12.64 strike

Q32 Bio Inc. director Mary Thistle was retroactively granted 10,826 stock options at an exercise price of $12.64 per share. These options, corrected from a previous filing, expire on June 11, 2036, and will vest fully on the earlier of June 12, 2027, or …

Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Q32 Bio Inc. (QTTB) stock, showing its current price of $15.21 with a daily increase of 1.08%. The article notes that there are currently no analyst ratings or earnings information available for Q32 Bio Inc. It …

Q32 Bio Inc. (QTTB) CEO gets 132,000 PSUs tied to $100,000,000 financing

Q32 Bio Inc. CEO Jodie Pope Morrison was granted 132,000 performance-based restricted stock units (PSUs) on July 6, 2026, which vested on July 16, 2026, after meting a $100 million financing condition. These PSUs are also subject to a three-year quarterly vesting schedule, bringing …

Q32 Bio (QTTB) awards 37,500-share PSU-linked grant to its CSO

Q32 Bio Inc. (QTTB) reported that its Chief Scientific Officer, Shelia M. Violette, acquired 37,500 shares of common stock on July 16, 2026. This award stems from the vesting of performance-based restricted stock units (PSUs) linked to the company securing at least $100,000,000 in …

Q32 Bio Announces $200 Million Public Offering of Shares and Pre-Funded Warrants

Q32 Bio Inc. has announced a $200 million public offering of shares and pre-funded warrants. Law firms Goodwin Procter LLP and McCarter & English LLP advised Q32 Bio Inc., while Wilmer Cutler Pickering Hale and Dorr LLP advised the underwriters for the offering. The …

Form S-3 Q32 Bio Inc For: 17 July By Investing.com

This article reports on the filing of Form S-3 by Q32 Bio Inc on July 17. The brief piece indicates that the filing was published on July 17, 2026, at 22:08. It also includes a stock performance note for QTTB, which was down 1.05%.

Q32 Bio: Bempikibart's Progress Keeps Me Bullish (NASDAQ:QTTB)

Q32 Bio's bempikibart (ADX-914) has shown promising results in Phase 2a trials for alopecia areata, including meaningful hair regrowth and a favorable safety profile, even with lasting benefits post-treatment. While these small, open-label trial results are encouraging and reinforce a bullish outlook for the …

QTTB Forecast — Price Target — Prediction for 2027